Lab Test

Tysabri Antibody

Tysabri® Antibody, Natalizumab

Test Codes

Order Reference Lab Send Out Miscellaneous, EPIC: LAB848, Viracor: 30040

Department

Send Outs

Specimen Collection Criteria

Collect (preferred specimen): One plain Red-top tube.

Also acceptable: One Gold-top SST tube.

Physician Office/Draw Specimen Preparation

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and freeze (-20°C/-4°F or below).

Preparation for Courier Transport

Transport: 1.0 mL serum, frozen (-20°C/-4°F or below). (Minimum: 0.5 mL)

Rejection Criteria

Specimens not collected and processed as indicated.

In-Lab Processing

Let specimen clot 30-60 minutes then centrifuge to separate serum from cells. Transfer serum to a plastic transport tube and freeze (-20°C/-4°F or below)’

Transport: 1.0 mL serum, frozen (-20°C/-4°F or below). (Minimum: 0.5 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): 14 days
Frozen (-20°C/-4°F or below): 14 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Eurofin/Viracor Reference Lab in Lenexa, KS.

Performed

Monday – Friday.
Results available in 5-7 days.

Reference Range

By report.

Test Methodology

Binding Assay

Clinical Utility

Tysabri® (natalizumab) is a monoclonal antibody therapy used to treat multiple sclerosis (MS), a serious autoimmune disease that results in damage to the brain and spinal cord. Patients being treated with Tysabri can develop Tysabri-specific antibodies that may block the therapeutic effect of the treatment.

CPT Codes

83516

Contacts

Last Updated

8/4/2025

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.